Loading
A first-in-class drug that blocks cortisol signalling in tumour cells, approved in 2026 for platinum-resistant ovarian cancer with chemotherapy.
Relacorilant is a selective glucocorticoid receptor antagonist that blocks cortisol signalling inside tumour cells, where glucocorticoid receptor activation is a mechanism of chemotherapy resistance, so it restores sensitivity to the taxane given alongside it. Corcept's ROSELLA phase 3 trial showed that relacorilant plus nab-paclitaxel improved both progression-free and overall survival versus nab-paclitaxel alone, and it was approved in Q1 2026 for platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, the first drug in its class. It is taken as 150 mg the day before, the day of and the day after each weekly nab-paclitaxel dose. Whether the approach extends to other chemotherapy-resistant cancers is open. For a newcomer: a drug that removes a stress-hormone shield so chemotherapy works again.
Selective GR antagonist restoring chemosensitivity.
1.Cortisol binds glucocorticoid receptors in tumour cells and switches on anti-apoptotic genes
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Source: www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications. Doses are for orientation; the current label governs.
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026). Approved 2025 for hypercortisolism; oncology use is investigational, and Part D plans will not cover off-label ovarian cancer use outside a compendium listing.
Covered with prior authorisation for the labelled endocrine indication only; ovarian cancer use is not yet on label.
Part D out-of-pocket capped at $2,000 (2025) / $2,100 (2026). Medicare patients cannot use manufacturer co-pay cards; charity funds (PAN, HealthWell, CancerCare) and the Extra Help subsidy are the routes.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.
Sources: NICE search: relacorilant. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
NDA submitted (ROSELLA) source
Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with nab-paclitaxel source
| Region | Year | Indication |
|---|---|---|
| US | 2026 | Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with nab-paclitaxel |
| Adverse event |
|---|
| Neutropenia |
| Anaemia |
| Fatigue |
| Nausea |
| Peripheral neuropathy |
| Hypokalaemia |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Relacorilant" OR ABSTRACT:"Relacorilant" OR TITLE:"Lifyorli" OR ABSTRACT:"Lifyorli") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Relacorilant, not a curated reading list.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer, Ovarian cancer.
Shares High-grade serous ovarian cancer, Ovarian cancer, Cytotoxic chemotherapy.
Shares Platinum-resistant ovarian cancer, Ovarian cancer, Cytotoxic chemotherapy.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer, Ovarian cancer.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer, Ovarian cancer.
Shares Platinum-resistant ovarian cancer, Ovarian cancer, Cytotoxic chemotherapy.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer, Ovarian cancer.
Shares Platinum-resistant ovarian cancer, Ovarian cancer, Cytotoxic chemotherapy.